Deprenyl in attention deficit associated with Tourette's syndrome.

While central nervous system stimulants usually improve attention deficit hyperactivity disorder (ADHD) associated with Tourette's syndrome, they often exacerbate tics and can produce other potentially serious complications. Because deprenyl may have a stimulatory effect and monoamine oxidase inhibitors have been shown to ameliorate hyperactive behavior, we studied this drug in children with the Tourette's syndrome-ADHD combination. Twenty-nine patients, 25 boys and four girls, with a mean age of 11.2 years (range, 6 to 18 years) and duration of symptoms for an average of 6.2 years (range, 1 to 13 years), were enrolled in this open trial after they became refractory to conventional treatments for ADHD. The average duration of treatment with deprenyl was 6.7 months (range, 3 to 15 months) and the average daily dose was 8.1 mg/d (range, 5 to 15 mg/dL). Twenty-six of all patients (90%) reported clinically meaningful improvement in their ADHD (score > or = 2 on a scale of 0 to 4), with the mean global improvement rated at 2.6. There were no serious adverse side effects and only two patients noted exacerbation of their tics. Deprenyl appears to be a safe and effective treatment of ADHD in patients with Tourette's syndrome.

[1]  M. Robertson,et al.  Pharmacologic controversy of CNS stimulants in Gilles de la Tourette's syndrome. , 1992, Clinical neuropharmacology.

[2]  R. Kurlan.  The pathogenesis of Tourette's syndrome. A possible role for hormonal and excitatory neurotransmitter influences in brain development. , 1992, Archives of neurology.

[3]  J. Rapoport,et al.  Tourette syndrome and obsessive-compulsive disorder. , 1992, Advances in neurology.

[4]  J. Jankovic.  Diagnosis and classification of tics and Tourette syndrome. , 1992, Advances in neurology.

[5]  H. Singer,et al.  Abnormal dopamine uptake sites in postmortem striatum from patients with tourette's syndrome , 1991, Annals of neurology.

[6]  M. Bhatia,et al.  Attention deficit disorder with hyperactivity among paediatric outpatients. , 1991, Journal of child psychology and psychiatry, and allied disciplines.

[7]  J. Sverd,et al.  Stimulants for ADHD in child patients with Tourette's syndrome: the issue of relative risk. , 1990, Journal of developmental and behavioral pediatrics : JDBP.

[8]  L. Sroufe,et al.  Treatment of attentional and hyperactivity problems in children with sympathomimetic drugs: a comprehensive review. , 1990, Journal of the American Academy of Child and Adolescent Psychiatry.

[9]  R. Kurlan.  Tourette's syndrome , 1989, Neurology.

[10]  D. Comings,et al.  Hypothesis: homozygosity in Tourette syndrome. , 1989, American journal of medical genetics.

[11]  M. Wolraich,et al.  Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. , 1989, Pediatric clinics of North America.

[12]  P. Szatmari,et al.  Ontario Child Health Study: prevalence of attention deficit disorder with hyperactivity. , 1989, Journal of child psychology and psychiatry, and allied disciplines.

[13]  G. Shady,et al.  Tourette Syndrome and social functioning in a Canadian population , 1988, Neuroscience & Biobehavioral Reviews.

[14]  Anthony E. Lang,et al.  Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.

[15]  H. Singer,et al.  Development of behavioral and emotional problems in Tourette syndrome. , 1989, Pediatric neurology.

[16]  D. Comings,et al.  A controlled study of Tourette syndrome. I. Attention-deficit disorder, learning disorders, and school problems. , 1987, American journal of human genetics.

[17]  J. Jankovic,et al.  Motor, Behavioral and Pharmacologic Findings in Tourette's Syndrome , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[18]  J. Rapoport,et al.  Treatment of Hyperactive Children With Monoamine Oxidase Inhibitors: I. Clinical Efficacy , 1985 .

[19]  J. Rapoport,et al.  New drug trials in attention deficit disorder. , 1985, Psychopharmacology bulletin.

[20]  P. Wender,et al.  Pharmacological treatment of attention deficit disorder, residual type (ADD,RT, "minimal brain dysfunction," "hyperactivity") in adults. , 1985, Psychopharmacology bulletin.

[21]  J. Frost,et al.  Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome , 1984, Neurology.

[22]  A. Lees,et al.  Clinical and pharmacological aspects of (-)-deprenyl treatment in Parkinson's disease. , 1983, Modern problems of pharmacopsychiatry.

[23]  Friedhoff Aj.  Receptor maturation in pathogenesis and treatment of Tourette syndrome. , 1982 .